Article
Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma.
The Laryngoscope - 1 May 1992
Melioli G, Margarino G, Scala M, Mereu P, Bertoglio S, Schenone G, Barbaresi M, Machí A M, Santi L, Badellino F
Abstract excerpt
Patients with advanced head and neck squamous cell carcinoma (HNSCC) are severely immunocompromised. In virtually all such patients who have been studied, reduced numbers of circulating CD3+ T-cell-receptor (TCR)alpha/beta+ T lymphocytes, a reduction of natural killer (NK) activity, and a poor induction of lymphokine-activated killer (LAK) cell activity (following in vitro treatment with recombinant interleukin-2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.